Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
November 7, 2023
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. Joining us on this call are our President and CEO, Howard Robin; our Chief of Research and Development, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; and our Chief Business Officer, Jennifer Ruddock. Regrettably, our acting Chief Financial Officer, Sandra Gardiner, couldn't be with us on today's call because of an unforeseen family emergency. During this call, we anticipate making forward-looking statements about our business, including statements about the therapeutic potential of and future development plans for drug candidates and research programs. This covers things like when clinical trials will begin, when data from those trials on drug candidates will become available, the schedule and intentions for sharing upcoming clinical results, whether our collaboration agreements will come together and how they'll progress or succeed, what we anticipate after the corporate restructuring and reorganization, our financial guidance, and a few other remarks about where our business is headed. Because these forward-looking statements concern things that haven't happened yet, they come with risks and uncertainties that are hard to foresee, and many of them lie beyond our ability to control. What actually happens could end up looking quite different from what these statements suggest. You can find the key risks and uncertainties laid out in our Form 10-Q filed on August 9, 2023, which you can access at sec.gov. We're not committing to revise any of these forward-looking statements — not because of fresh information, later events, or anything else. You'll be able to find a webcast of today's call on the IR section of Nektar's site, nektar.com. With that covered, I'll pass things along to Howard Robin, our President and CEO. Howard?
Howard Robin
executiveThank you, Vivian, and I appreciate everyone being here with us today. During Q3, we achieved significant strides in moving our development programs forward. To start with REZPEG, we're happy to report that in October we started activating the initial clinical sites for the Phase 2b study of REZPEG in atopic dermatitis patients. We anticipate receiving the initial results from this trial, focused on the primary endpoint of EASI reduction across the 16-week induction period, at some point during the first half of 2025. The robustness of the findings from our randomized Phase 1b trial leaves us quite hopeful that the Phase 2b trial will succeed. Those findings were shared not long ago at the 2023 EADV meeting during an oral late-breaking news plenary session, and JZ will go over some of the fresh data that was presented later in this call. But what matters greatly is that we saw a steady advantage with REZPEG as monotherapy across numerous clinical efficacy endpoints and patient-reported outcomes. As Dr. Silverberg noted during his plenary presentation, the Phase 1b trial of REZPEG stands as the first randomized placebo-controlled study to provide compelling proof of concept regarding the significant contribution of T regulatory cells in addressing autoimmune disease. And it was thrilling to observe that this advantage persisted for numerous patients all the way through 36 weeks after the treatment concluded. This considerable advantage seen with REZPEG might remove the requirement for regular maintenance dosing among atopic dermatitis patients, and it places REZPEG, with its novel regulatory cell mechanism, as a possible new therapeutic choice that might prove extremely disruptive within the biologic treatment landscape for atopic dermatitis. The biologic market for atopic dermatitis represents a multibillion dollar market that is expanding. This landscape encompasses numerous IL-13-based mechanisms that overlap with each other. And REZPEG brings the distinct promise of a fresh mechanism within this landscape along with a new treatment paradigm that is well tolerated. That's the reason we hold such optimism regarding REZPEG's potential. Our objective is to make sure enrollment stays on track to produce results from the randomized Phase 2b trial according to our planned time line in the first half of 2025. During the last quarter, we broadened our plan for a second study in alopecia areata, moving from its initial randomized Phase 2a study design of approximately 40 patients to a randomized Phase 2b study design of approximately 80 patients. This aligns with standard studies in this field, and the added cost of this study remains within our projected budget. Importantly, this study will report results at roughly the same time as the atopic dermatitis study; we think there's a chance for REZPEG to emerge as a novel biologic mechanism in alopecia, which currently has no approved biologic treatments and where JAK inhibitors serve as the main treatment mechanism; we recognize that JAK inhibitors carry cardiac safety concerns and that patients face a rebound once they stop therapy; therefore, there's a substantial unmet medical need among those patients for a new treatment option. Given all the data we've accumulated so far on REZPEG in atopic dermatitis along with other autoimmune conditions, we feel there's a solid scientific basis for REZPEG, through its Treg mechanism, to target the root pathogenesis of alopecia, and JZ is going to walk through the study's scientific rationale shortly. Our plan is to file the IND for this trial with the FDA before the year is out, and we anticipate kicking off the study soon after that; beyond this, we keep moving our immunology preclinical efforts forward, which includes our TNFR2 agonist antibody, a mechanism that looks promising for multiple sclerosis, ulcerative colitis, and additional autoimmune indications too. For this antibody program, our aim is to submit an IND during 2024. Turning to NKTR-255, we're happy to have just shared news of our fresh clinical research partnership with Cellular Biomedicine Group, or CBMG, to assess NKTR-255 alongside CBMG's TIL therapy in lung cancer patients who don't respond to anti-PD-1 therapy. CBMG is incorporating NKTR-255 into its existing Phase 1 trial taking place at Duke University Cancer Institute and other investigator sites across the U.S. We're likewise carrying on our remaining clinical efforts with NKTR-255 as we look into further strategic partnership avenues for the program; the quarter closed with us in a robust financial position, holding $373 million in cash. And as I mentioned before, we're well situated to push forward our planned clinical studies while keeping a cash runway extending into the middle of 2026. The objective is to hit multiple value-enhancing Phase 2 milestones for REZPEG during the first half of '25, and we think we're well positioned to deliver on that. Because a lot of you have been inquiring about where things stand in our litigation with Lilly, I'll offer a quick note that we're still actively pursuing the litigation and stay confident in our legal position. With that, I'll pass the call to JZ for an R&D discussion. JZ?
Jonathan Zalevsky
executiveThanks, Howard. I'll begin with REZPEG, the immunology asset that leads our pipeline. Howard already mentioned this, but this program holds a distinctive spot as the furthest-along IL-2-based Treg mechanism being studied in humans, and it could address several autoimmune conditions, among them the two we're prioritizing right now: atopic dermatitis and alopecia areata. During a late-breaking abstract session at the 2023 EADV congress, Dr. Jonathan Silverberg shared strong REZPEG data last month from the Phase 1b atopic dermatitis trial. That session, which covered the trial's final results, underscored what REZPEG might offer as an atopic dermatitis treatment. Across the 12-week induction period, REZPEG produced dose-dependent efficacy on both physician-assessed and patient-reported measures of efficacy, and many of those measures hit statistical significance. What's more, we're highly encouraged by the durability REZPEG showed well beyond the close of that 12-week induction period. A large number of patients keep their disease under control for another 36 weeks once dosing has stopped. You don't see that kind of extended disease control after dosing ends with Dupilumab or with JAK inhibitors. Response came quickly: more than 40% of atopic dermatitis patients hit EASI 75 by week 3, after just 2 doses of REZPEG at the top dose level. REZPEG's speed of onset is on par with JAK inhibitors, which so far have beaten Dupilumab in head-to-head studies on that front. We also saw durability of the EASI 75 response, with roughly 70% of EASI 75 responders holding onto their response for 36 weeks following the close of the 12-week induction period. That's a really exciting finding, and it points to REZPEG possibly becoming the first immunotherapy available for atopic dermatitis. On top of that, REZPEG was well tolerated, and patients on REZPEG did not develop antidrug antibodies, something that has been reported in certain cases within the IL-2 mutein class. Relative to placebo, the REZPEG treatment arms showed sustained gains in the absolute counts of circulating total and CD25bright Tregs. In the highest REZPEG dose group, the large rise in CD25bright Treg numbers reached tenfold above baseline. Even though the induction period of 12 weeks was shorter than usual — most other biologics use a 16- to 24-week induction period — all efficacy endpoints improved clearly, among them EASI scores, the vIGA, BSA, Itch-NRS, DLQI and POEM. Those gains start as early as weeks 2 to 4 and carry on through week 12 of treatment. For some context, in historical atopic dermatitis studies at the lower REZPEG dose level, the improvements we observed resembled those seen with biologic therapy. And at the higher dose level, REZPEG showed activity comparable to what has been reported for JAK inhibitors. That 83% improvement in EASI score at baseline, seen after just 12 weeks of induction with REZPEG, was better than what the Dupilumab trials showed at 16 weeks. These encouraging findings have both us and KOLs quite excited about the possibility of durable responses and about frequent maintenance dosing with REZPEG in atopic dermatitis. What we've achieved with REZPEG thus far matters for several reasons. First, prior to this work, not much was understood about whether restoring Treg function could reverse immunological pathogenesis and lessen the severity of dermal or cutaneous disease. With REZPEG and its Treg mechanism, we've now shown clinical efficacy against the cutaneous manifestations of lupus, psoriasis and atopic dermatitis; these findings start to validate the Treg mechanism as a way to treat multiple skin pathologies. REZPEG's appealing mechanism harnesses the body's own immune system to restore tolerance by inducing the Treg pathway, and it offers a novel approach distinct from existing broad or targeted strategies that block inflammatory pathways in dermal diseases like atopic dermatitis. Second, we hypothesize that giving the agonist drug REZPEG induces Treg expansion and engages multiple immunoregulatory mechanisms, promoting immune tolerance and regulation by attenuating Th1, Th2 and Th17 effector T cells, suppressing antigen-presenting cell activity and encouraging tolerogenic dendritic cells. We think this science explains the durability of response we saw in the atopic dermatitis trial and is the differentiating factor enabling us to pursue an every 3-month dosing regimen in our ongoing Phase 2b atopic dermatitis study. From a biological standpoint, REZPEG, through its central pathway of Treg rescue, is uniquely positioned to address the diversity of immunopathology, offering broad potential for targeting multiple dermal diseases, including atopic dermatitis, alopecia areata and others. In October, we started the Phase 2b study of REZPEG in biologic-naive atopic dermatitis patients. Our aim is to enroll approximately 400 patients, testing 3 different REZPEG regimens against placebo, assessed across a 16-week induction period. Following induction, patients who reach a threshold to move from induction into maintenance will be rerandomized into 1 of 2 maintenance regimens at different dosages, on either a once a month or once every 3-month dosing schedule, continuing for another 28 weeks. We anticipate this study will take roughly 54 weeks to run, with data expected in the first half of 2025; we also intend to launch a Phase 2b study of REZPEG in alopecia areata later and early next year. Alopecia areata is an indication with a high clinical unmet need for a biologic, since the only approved agents are JAK inhibitors, which carry a black box warning and lack durability after dosing stops. So because of all that, we think REZPEG could turn into a first-of-its-kind biologic treatment for alopecia areata. And like I said a moment ago, we see REZPEG, with the way it works through Tregs, as having real promise for this condition, which is basically a skin disorder affecting the scalp. Looking across every study we've run, with close to 600 individuals dosed, REZPEG shows a steady and extremely consistent Treg cell pharmacodynamic pattern across various autoimmune disease pathologies and even among healthy volunteers. When you put that all together, we feel there's a solid scientific basis for using REZPEG to treat alopecia. The Phase 2b trial is expected to enroll about 80 patients who have moderate-to-severe alopecia, and they'll be assigned randomly to either REZPEG or placebo. As Howard said, although our earlier plan was to conduct a Phase 2a trial enrolling about 40 patients, after going through prior trials in this indication, we chose to expand the study so we could get a Phase 2b design while adding only minimal cost. Treatment will last 36 weeks, with patients followed for as long as 48 weeks overall. The main endpoint we're measuring is mean percent improvement in salt, or the severity of alopecia too, at week 36 — something quite standard in females. We'll also be evaluating several other secondary endpoints, such as the proportion of patients showing a reduction in salt. Let me now shift to our top immunology research effort, a TNFR2 agonist antibody program. TNFR2 shows high expression on Tregs, neuronal cells and other cell types, and TNFR2 agonism has been demonstrated to strengthen the suppressive impact and overall functional characteristics of Tregs. When TNFR2 is missing, it's linked to autoimmunity and other genetic conditions that resemble FoxP3 loss of function. On the other hand, having it has been tied to immunoregulatory activity and protective benefits across many cell populations and tissues within the body. Given everything we understand about the potential of regulatory T cell mechanisms, this program strikes us as extraordinarily exciting. Nektar has found 2 lead antibodies that we've now confirmed for selective TNFR2 binding, cell type specificity, and TNFR2 agonism in primary human cell-based assays. We think a selective TNFR2 agonist carries tremendous promise for treating numerous autoimmune diseases, and we're pushing hard on this program, on track to file our IND in 2024. At this point I'd like to hand the call over to Mary for a quick update on our NKTR-255 program in oncology and our new collaboration with CBMG. Mary?
Mary Tagliaferri
executiveThanks, JZ. Turning now to NKTR-255: our efforts with NKTR-255 are ongoing as we assess possible strategic partnership routes; in our view, NKTR-255 may have wide-ranging potential uses in boosting how well cellular therapies work. Along those lines, as Howard said before, we're glad that we recently made public a new clinical research partnership with a top cell therapy firm, Cellular Biomedicine Group, to test NKTR-255 together with their TIL therapy called C-TIL051. That trial, run and completely paid for by CBMG, focuses on advanced non-small cell lung cancer patients who don't respond to anti-PD-1 therapy. Since these people have limited treatment choices, we're enthusiastic about what this regimen might do for patients. Data from preclinical and early clinical work indicate that IL-15 may boost the expansion and durability of cellular therapies like TIL, raising targeted anti-tumor activity. The initial investigator location is Duke University, alongside a lung cancer research leader, Dr. Scott Antonia. If this study yields favorable results, it might open a route toward accelerated approval pursued by our partner, CBMG. Additional trials of ours in cell therapy are ongoing, and we anticipate possible data from these studies being reported next year, among them the Phase 2 JAVELIN Bladder Medley Study, run and funded by our partner, Merck KGaA. Given its distinctive promise as a combination agent alongside cell therapies and other mechanisms, we're looking into the optimal partnership and development route for NKTR-255's continued development. With that, I'll hand the call to Jennifer for a review of our financial guidance. Jennifer?
Jennifer Ruddock
executiveThanks, Mary, and good afternoon to all of you; we closed out the third quarter holding $373 million in cash and investments, and there is no debt on our balance sheet. Our current expectation is that we will finish this year with at least $320 million in cash and investments, which is a bit above the $315 million we projected previously. As was announced earlier in the year, we cut our San Francisco-based workforce by roughly 60%, and that reduction in personnel translates to about $30 million per year in lower operating expense. The restructuring-related costs were largely paid out in June. Thanks to this restructuring, we will see the full annual savings during 2024. Our financial position is still solid, with a cash runway reaching into the middle of 2026. Importantly, that runway carries us through a number of key value-generating milestones for our pipeline; during Q3, we took a $10 million non-cash impairment charge tied to real estate leased assets in San Francisco, which added $0.05 to our net loss per share for the quarter. Consequently, for the full year, we now anticipate recognizing restructuring, impairment and costs of terminated programs of roughly $50 million to $55 million, and that figure includes $37 million of non-cash impairment charges recognized through the first 9 months of 2023. Our Form 10-Q, being filed this afternoon, contains more detail on this. For full-year 2023, we now expect G&A operating expense to come in between $80 million and $85 million, including approximately $15 million to $20 million of non-cash depreciation and stock comp expense. Our GAAP revenue for full-year 2023 is still expected to land between $80 million and $90 million. That revenue includes $65 million to $70 million in non-cash royalties plus $15 million to $20 million in product sales. We anticipate full-year GAAP R&D operating expenses will fall in the range of $105 million to $115 million, including approximately $15 million to $20 million of non-cash depreciation and stock comp expense. Our full-year non-cash interest expense should be between $20 million and $25 million. As I said earlier, we expect to finish this year with at least $320 million in cash and investments. With that, we will now open the call for questions. Crystal?
Jay Olson
analystNice work on the advancement, and I appreciate this update. Could you discuss the Phase 2b trial in atopic dermatitis? Also, congratulations on getting that study started. Could you share what feedback you're getting from investigators? At what point do you anticipate giving some guidance regarding enrollment rates? And when do you anticipate finishing recruitment for that trial?
Jennifer Ruddock
executiveSure, I'll turn it over to Mary, since she's been speaking with many of these investigators during the last couple of months, to weigh in on that. Mary?
Mary Tagliaferri
executiveAt EADV in Berlin not long ago, we had the chance to sit down with 30 investigators, the majority of them based in Europe. This study will enroll patients across 100 clinical sites located in the US, Canada, Europe, and Australia. I can share that these investigators are genuinely enthusiastic about REZPEG, how it works, and what it could mean for atopic dermatitis. Dr. Jonathan Silverberg's presentation drew a strong crowd and got a great response. Jonathan Silverberg pointed out that while the significance of T regulatory cells has been understood for many years, no data had ever emerged from a drug capable of actually expanding those cells to help dermal conditions like atopic dermatitis — and with an 83% drop in mean EASI score from baseline, he described it as best in industry. So enthusiasm among the investigators is broad. A few other aspects of our clinical trial are quite compelling as well. First, our safety profile looks strong. The drug is highly tolerable, and we've demonstrated that in roughly 600 patients. Second, investigators really favor the maintenance approach we plan to study, testing a monthly regimen alongside one given every 3 months; and third, the ability for their patients to keep receiving REZPEG past the 16-week induction period appeals greatly to both the patients and the investigators. Given all this, we're confident we can complete the trial on track and on time, with topline data ready in the first half of 2025. I hope that answers your question.
Jay Olson
analystYes, and we'll be eager to hear more updates down the road. Regarding the Phase 2b trial of REZPEG in alopecia areata, could you share your thoughts on dosing? And what threshold must be met before starting a Phase 3 study? Also, how do you plan to measure REZPEG's results against oral medications for alopecia that were approved recently?
Jennifer Ruddock
executiveMary or JZ, do either of you want to address that?
Mary Tagliaferri
executiveAbsolutely, I'll take that question. As everyone knows, JAK inhibitors do work well. We tend to observe results at about the 36-week mark of therapy. As you're aware, JAK inhibitors come with a number of drawbacks. First, once patients discontinue a JAK inhibitor, hair loss returns very quickly; and naturally, you're all familiar with the boxed warning attached to JAK inhibitors. We took a very careful look at the baricitinib data, and our view is that if our efficacy matches baricitinib's, while avoiding 2 things — first, swift hair shedding once treatment stops, or second, the need for a maintenance approach that, much like what we're examining in atopic dermatitis, is considerably more convenient and patient-friendly — then a biologic, we believe, would be highly attractive for alopecia areata. Our plan is to test 2 separate doses against placebo, with assessment at 36 weeks. And again, in my view, efficacy that is comparable to or better than what JAK inhibitors have shown, alongside a better safety profile, better tolerability, and no boxed warnings, would position REZPEG as strongly competitive in this space.
Charlie Ferranti
analystCharlie here, sitting in for Chris. Nice work on the advances. We've got a couple of fast questions. To start, regarding the strategic partnership plans for NKTR-255, is there anything new on when that partnership is expected? As I recall, the prior goal was year-end '23 — is that still the plan, or is there a different time line in mind now? Then, about the pipeline that follows, with the TNFR2 IND arriving next year, is there anything new on the PEG-CSF1 program, and should we look for an IND from it closer to the 2025 sort of scale?
Jennifer Ruddock
executiveHoward, please handle the first part of that question about NKTR-255; and then JZ, would you take the question about the preclinical program.
Howard Robin
executiveYeah, absolutely. That's a fair question. So NKTR-255 is a really promising program, in our view. We've been in discussions with multiple companies. As you know, we recently wrapped up a partnership with CBMG involving TIL therapy, and we've got a collaboration with Merck KGaA focused on bladder cancer. So a lot is happening around NKTR-255. On top of that, we're running our own trial at the Fred Hutchinson Cancer Center in cell therapy. So yes, there are parties that have shown interest. I'd say our goal is to finalize a strategic partnership for NKTR-255. As an organization, our primary emphasis is now on immunology, even though I believe this is a really compelling asset. I'm not able to share details about the timing or the manner in which such a partnership would come together, but we're making solid headway. And like you saw with the CBMG deal, we've just brought in yet another promising possible use for NKTR-255. So we'll keep everyone updated. Whether it happens by the close of this year or sometime next year, I can't say with certainty. But it's clearly something we're prioritizing, and I genuinely believe it will come to fruition. JZ, could you take the PEG-CSF1 question?
Jonathan Zalevsky
executiveSure. Right now, we've really put our main focus on the TNFR2 program, and there are a couple of reasons behind that. First, TNFR2 works through a complementary pathway involving Treg targeting, and that pathway is separate from the IL-2 pathway that REZPEG acts on. For instance, you're aware that TNFR2, being part of the TNF superfamily, ranks among the most potent signals that drive NF-kappa B in cells such as Tregs, and it also stands among the most powerful signals for regulating FoxP3 expression, which is a key enzyme for suppressive as well as differentiated and robust Treg responses, correct? When FoxP3 is lost, Tregs undergo de-differentiation. So it's genuinely a target that's extremely, extremely hot right now; it truly grew out of the knowledge we've gained from our extensive work with REZPEG and in the Treg space. And it additionally enables us to apply everything we've learned and push our prioritized efforts forward into TNFR2. That's really where our attention sits at the moment. As for the PEG-CSF program, we'll pursue that later on, but TNFR2 is truly what we're concentrating on today. I'd add that since we've had the chance to talk about that program with certain outside parties, a great deal of interest has come our way regarding it. We're seeing plenty of organizations — pharmas, large biotechs, and others — that have genuinely carved out room for TNFR2 within their strategies; so much is understood about TNF inhibition through medicines such as HUMIRA, golimumab, infliximab, Enbrel, and similar ones that have made such a deep impact on rheumatology. Over that stretch of time, we've come to understand the TNFR1 and TNFR2 receptor axis and what gets missed when you simply block every TNFR and its signaling, which also means blocking the TNFR2 pathway; so this is something that has us quite enthusiastic. We're pleased with all the interest and with where we're directing our energy. We're thrilled to be on track. We're entering our cell line stage, moving toward the manufacturing setting. And we remain on track to submit our IND in 2024, next year, for that program.
Howard Robin
executiveOkay, thanks to all of you for being here today, and our attention stays fixed on carrying out the work of developing REZPEG along with the research programs centered on immunology. I believe a clear route ahead has been set for us. My appreciation goes out to each of our staff members for what they put in and their diligence, and I also want to express gratitude to our investors for sticking with us; we're eager to bring you news about how things are advancing. Keep watching, and thank you for being with us today.
Operator
operatorThat wraps up the conference call for today. We appreciate everyone taking part. You're free to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.